SynDevRx to Present AMELIA™-1 Data at ASCO 2026 Showing Improved PI3K/AKT Class Inhibitor Responses in Breast Cancer
Evexomostat combination shows clinical benefit and favorable safety in heavily pretreated HR+/HER2− mBC patients with PI3K pathway alterations. CAMBRIDGE, MA, UNITED STATES, May 19, 2026 /EINPresswire.com/ -- SynDevRx, Inc., a clinical-stage oncology …